PRGN-3006
- Generic Name
- PRGN-3006
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface.
- Associated Conditions
- -
- Associated Therapies
- -
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
Precigen reports Q3 2024 financial results and business updates, including completion of pre-BLA meeting with FDA for PRGN-2012, commercial and manufacturing readiness for potential 2025 launch, initiation of confirmatory clinical trial for PRGN-2012, and preparation for end of Phase 1b meeting with FDA for PRGN-3006 in AML. Preclinical data for PRGN-3008 presented at SITC 2024 showcasing potential as best-in-class CD19-targeting CAR-T treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath